We are driven to wake up a dormant therapeutic area and usher in a new era of treatment for patients with acid-related disorders


Phathom Pharmaceuticals is working to change the GI treatment landscape and improve the lives of patients with acid-related disorders. Phathom is developing a potassium-competitive acid blocker (PCAB).

Phathom’s development programs are described in the Clinical Trials & Pipeline section linked below.

Phathom is aiming to disrupt the status quo and bring a fresh approach to treating acid-related GI disorders through our clinical programs